• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Parkinsonism & related disorders >A single-blind cross over study investigating the efficacy of standard and controlled release levodopa in combination with entacapone in the treatment of end-of-dose effect in people with Parkinson's disease.
【24h】

A single-blind cross over study investigating the efficacy of standard and controlled release levodopa in combination with entacapone in the treatment of end-of-dose effect in people with Parkinson's disease.

机译：一项单盲交叉研究，研究了标准和控释左旋多巴与恩他卡朋联合治疗帕金森氏病患者的剂量终止效应的疗效。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: To determine the efficacy of standard levodopa combined with controlled release levodopa and entacapone in controlling end-of-dose symptoms in Parkinson's disease. METHODS: A single-blind cross over design was used to compare the duration of action for three pharmacological combinations: standard levodopa (L/DDC); standard levodopa combined with entacapone (L/DDC/E); and standard levodopa combined with controlled release levodopa (CR) and entacapone (L/DDC/CR/E). Thirty two participants with wearing-off symptoms and inadequate symptom control with L/DDC/E had their optimum dose of L/DDC determined at base line. Entacapone was added to the optimal L/DDC dose and duration of action determined. Levodopa CR dosage was adjusted to match the optimal L/DDC dose for each participant. All participants were then trialed on L/DDC/CR/E and duration of response calculated. Timed Up and Go (TUG) times and magnitude of extra movements were recorded hourly throughout the day over several days to determine the optimum interval between doses for each combination. The UPDRS (Sections 2 and 3), PDQ39 and fatigue scale, the PDF-16, were recorded at base line and when dosage intervals had stabilized on L/DDC/CR/E. RESULTS: Duration of response was greatest with L/DDC/CR/E compared to L/DDC/E (p < 0.001) and number of daily doses were less on L/DDC/CR/E compared to L/DDC/E (p < 0.001). UPDRS, PDQ39 and fatigue scores also improved on L/DDC/CR/E compared to L/DDC (p < 0.001). Dyskinesia increased on L/DDC/CR/E (p = 0.001) however magnitude was mild. CONCLUSION: Combining standard levodopa and levodopa CR preparations with entacapone is an additional treatment strategy to manage motor fluctuations in advanced PD.
机译：目的：确定标准左旋多巴与控释左旋多巴和恩他卡朋联合使用在控制帕金森氏病剂量终止症状中的功效。方法：采用单盲交叉设计比较三种药物组合的作用持续时间：标准左旋多巴（L / DDC）;左旋多巴（L / DDC）;左旋多巴（L / DDC）。标准左旋多巴联合他卡朋（L / DDC / E）;和标准左旋多巴与控释左旋多巴（CR）和entacapone（L / DDC / CR / E）结合使用。 L / DDC / E症状消失且症状控制不充分的32名参与者在基线时确定了他们的L / DDC最佳剂量。将恩他卡朋添加到最佳L / DDC剂量并确定作用时间。调整左旋多巴CR剂量以匹配每个参与者的最佳L / DDC剂量。然后对所有参与者进行L / DDC / CR / E试验，并计算反应持续时间。在几天中的每一天中，每小时记录一次定时起跑（TUG）时间和额外运动的幅度，以确定每种组合的两次剂量之间的最佳间隔。在基线和剂量间隔稳定在L / DDC / CR / E上时记录了UPDRS（第2和第3节），PDQ39和疲劳量表PDF-16。结果：与L / DDC / E相比，L / DDC / CR / E的反应持续时间最大（p <0.001），与L / DDC / E相比，L / DDC / CR / E的日剂量减少（ p <0.001）。与L / DDC相比，L / DDC / CR / E的UPDRS，PDQ39和疲劳评分也有所提高（p <0.001）。 L / DDC / CR / E的运动障碍增加（p = 0.001），但是轻度。结论：将标准左旋多巴和左旋多巴CR制剂与他卡朋组合使用是治疗晚期PD运动波动的另一种治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号